Lightning-Link® In-licensing Deal Enhances ImmunoReagents’ Product Offering to the Diagnostic Industry

ImmunoReagents, the global manufacturer of high quality antibody products to the diagnostic and research industry, has entered into a non-exclusive in-licensing deal to use Innova Biosciences (Cambridge, UK) Lightning-Link® technology for commercial purposes.

Through the commercialisation deal, ImmunoReagents will utilise Innova’s technology for the manufacture of antibody conjugates, taking advantage of the very rapid Lightning Link conjugation protocol that offers 100% yield with enhanced sensitivity in comparison to traditional methods. Such tools are critical to the diagnostic industry; the licensing deal will allow ImmunoReagents to provide enhanced products to facilitate technology development, whilst simultaneously maintaining an effective supply chain when the diagnostic kits are launched into the market place.

Commenting on the agreement ImmunoReagent’s CEO, Dr Ann Black, said, “ImmunoReagents is constantly searching for new technologies to improve our product base and we are pleased to incorporate Innova’s Lighting-Link technology for antibody conjugation.”

Dr Andy Lane, Executive Director at Innova Biosciences, said, “This deal is a perfect example of how Lightning-Link is increasingly being used by high quality manufacturers to both maximise efficiency and increase their product offerings.”

About ImmunoReagents Inc

ImmunoReagents is a leading global manufacturer of quality antibodies and reagents used in research and in vitro diagnostics. They offer a wide range of secondary antibodies covering a broad spectrum of immunoglobulins from various species. ImmunoReagents also provides custom manufacturing to meet specific customer requirements while adhering to cGMP guidelines and ISO quality systems requirements. The Company is located on NCSU’s Centennial Campus, a 1000 acre advanced technology community for university, government and industrial partners.